公开(公告)号：US12202892B2

公开(公告)日：2025-01-21

申请号：US16839249

申请日：2020-04-03

Applicant: Janssen Biotech, Inc.

Inventor： Marc Chevrier ,  Jarrat Jordan

IPC: A61K39/395 ,  A61K47/12 ,  A61K47/26 ,  A61P37/02 ,  C07K16/24 ,  A61K9/00 ,  A61K31/4706 ,  A61K31/519 ,  A61K31/573 ,  A61K39/00

Abstract: Methods for administration of an anti-IFN-α/-ω antibody by subcutaneous or intravenous administration in a clinically proven safe amount are provided. Also provided are methods for clinically proven safe treatment of IFN-I mediated diseases, such as systemic lupus erythematosus (SLE), by subcutaneous or intravenous administration of an anti-IFN-α/-ω antibody.

公开(公告)号：US12009079B2

公开(公告)日：2024-06-11

申请号：US16663527

申请日：2019-10-25

Applicant: Janssen Biotech, Inc.

Inventor： Matteo Cesaroni ,  Marc Chevrier ,  Jarrat Jordan ,  Jessica Schreiter

IPC: C07K14/56 ,  C12Q1/6809 ,  G16H20/10 ,  G16H50/30

CPC classification number: G16H20/10 ,  C07K14/56 ,  C12Q1/6809 ,  G16H50/30 ,  C07K2317/565 ,  C12Q2539/00 ,  C12Q2545/114

Abstract: Type I interferon (IFN-I) signatures are useful in methods of diagnosing whether a subject (or patient) with IFN-I mediated disease will be responsive to treatment with an IFN-I inhibitor and treating or refraining from treating the subjects.

公开(公告)号：US11197913B2

公开(公告)日：2021-12-14

申请号：US16993556

申请日：2020-08-14

Applicant: Janssen Biotech, Inc.

Inventor： Marc Chevrier ,  Kamyar Farahi ,  Newman Yeilding

IPC: A61K39/395 ,  C07K16/24 ,  A61K38/20 ,  A01K67/027 ,  A61K39/00 ,  C07K14/54 ,  A61K35/12

Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.

公开(公告)号：US10765724B2

公开(公告)日：2020-09-08

申请号：US15471790

申请日：2017-03-28

Applicant: Janssen Biotech, Inc.

Inventor： Marc Chevrier ,  Kamyar Farahi ,  Newman Yeilding

IPC: A61K38/20 ,  A61K39/395 ,  C07K16/24 ,  A01K67/027 ,  A61K39/00 ,  C07K14/54 ,  A61K35/12

Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.

公开(公告)号：US20180036379A1

公开(公告)日：2018-02-08

申请号：US15471790

申请日：2017-03-28

Applicant: Janssen Biotech, Inc.

Inventor： Marc Chevrier ,  Kamyar Farahi ,  Newman Yeilding

IPC: A61K38/20 ,  C07K16/24 ,  A61K39/00 ,  A61K39/395 ,  A01K67/027 ,  C07K14/54

Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.

公开(公告)号：US20200317771A1

公开(公告)日：2020-10-08

申请号：US16839249

申请日：2020-04-03

Applicant: Janssen Biotech, Inc.

Inventor： Marc Chevrier ,  Jarrat Jordan

IPC: C07K16/24 ,  A61P37/02 ,  A61K47/12 ,  A61K47/26

Abstract: Methods for administration of an anti-IFN-α/-ω antibody by subcutaneous or intravenous administration in a clinically proven safe amount are provided. Also provided are methods for clinically proven safe treatment of IFN-I mediated diseases, such as systemic lupus erythematosus (SLE), by subcutaneous or intravenous administration of an anti-IFN-α/-ω antibody.